PRIVA-MOXIFLOXACIN TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
09-12-2015
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
제공처:
PHARMAPAR INC
ATC 코드:
J01MA14
INN (International Name):
MOXIFLOXACIN
복용량:
400MG
약제 형태:
TABLET
구성:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
관리 경로:
ORAL
패키지 단위:
100
처방전 유형:
Prescription
치료 영역:
QUINOLONES
제품 요약:
Active ingredient group (AIG) number: 0142242001; AHFS:
승인 상태:
CANCELLED POST MARKET
승인 날짜:
2019-08-29
제품 특성 요약
_Priva-MOXIFLOXACIN _
_ _
_Page 1 of 60 _
PRODUCT MONOGRAPH
PR PRIVA-MOXIFLOXACIN
Moxifloxacin Tablets
(as moxifloxacin hydrochloride)
400 mg
Antibacterial Agent
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
October 16, 2015
Mont-Royal
Qc, H4T 1E2
CONTROL #: 187798
_Priva-MOXIFLOXACIN _
_ _
_Page 2 of 60 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
12
DRUG INTERACTIONS
............................................................................................................................
15
DOSAGE AND ADMINISTRATION
........................................................................................................
17
OVERDOSAGE
..........................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
19
STORAGE AND STABILITY
....................................................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............
전체 문서 읽기
